Revolution Medicines, Inc.
RVMD
Classement en actions
#572
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Prix de l'action
$197.08
Capitalisation boursière
$42.24B
Changement (1 jour)
0.27%
Changement (1 an)
268.44%
Pays
US
Échange Revolution Medicines, Inc. (RVMD)
Catégorie
Healthcare
Revenus pour Revolution Medicines, Inc. (RVMD)
Revenus en Jun 2026 TTM : 0.00
Selon les derniers rapports financiers de Revolution Medicines, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0.00. En 2023, l'entreprise a réalisé un chiffre d'affaires de $11.58M une diminution par rapport à le chiffre d'affaires de l'année 2022, qui était de $35.38M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Revolution Medicines, Inc. de 2017 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | $11.58M | -67.27% |
| 2022 | $35.38M | 20.38% |
| 2021 | $29.39M | -31.62% |
| 2020 | $42.98M | -14.10% |
| 2019 | $50.04M | 148.16% |
| 2018 | $20.17M | 0.00% |
| 2017 | 0.00 | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
